Skyrizi has knocked Dupixent off its pedestal and claimed the top spot for ad impressions by Rx and over-the-counter (OTC) brands in April.
The treatment for Crohn’s disease, psoriasis and psoriatic arthritis generated an impressions share of voice (SOV) of 7.27% and 2.4 billion impressions during the month, according to data released by iSpot.tv Friday morning.
The drug from Boehringer Ingelheim and AbbVie had an estimated national TV ad spend of $29.8 million, with NBC leading as the top network for impressions SOV and NBC Nightly News With Lester Holt serving as the top program for impressions SOV. Skyrizi also clocked in with the highest national TV ad spend among the brands in the top 10.
Finishing as a runner up was Dupixent, which had an impressions SOV of 7.18% and 2.4 billion impressions. The eczema and asthma drug from Sanofi and Regeneron also had an estimated national TV ad spend of $23.8 million. Dupixent led ad impressions among Rx and OTC brands in March, January and all of 2022.
For the second straight month, third place went to Rinvoq, with an impressions SOV of 5.42% and 1.8 billion impressions. The eczema, ulcerative colitis and arthritis treatment from AbbVie had an estimated national TV ad spend of $28.6 million.
Rounding out the top five were Bayer’s Astepro and Sanofi’s Allegra, which had an impressions SOV of 2.2 billion and 1.9 billion, respectively.
The bottom half of the rankings included Flonase, Claritin, Trelegy, Vraylar and Jardiance, in that order. Of note, Claritin had the smallest estimated national TV ad spend among the brands in the top 10 with $4.6 million.
Falling off the list were Bristol Myers Squibb’s Sotyktu and Eli Lilly’s Mounjaro, while GSK’s Trelegy and AbbVie’s Vraylar marked new additions.
Also gone from the list was the vaunted Vick’s, which held the top spot in February and finished in fourth place in March. The cough and cold relief drugs brand from Procter & Gamble slid in the rankings as the nation exits flu season and enters allergy season.
